← Search another drug
PatientPulse · by PatientPartner
Veozah fezolinetant
Moderate confidence
~51 public patient corpus pages analyzed, encompassing approximately 130 individual patient reviews and forum posts across Drugs.com, WebMD, Inspire, breastcancer.org, and Mayo Clinic Connect.
Executive intelligence
The signal that moves starts & adherence
55%Positive sentiment in discussion
1,937FDA adverse-event reports
20%Flagged serious
98%Reports name female patients
The single highest-leverage commercial moment is the 3-to-6-month efficacy fade window, where patients who felt "cured" abruptly lose relief and abandon therapy without peer support or a clinical re-engagement plan.
- Veozah earns strong initial satisfaction among breast cancer survivors and HRT-ineligible women, with many describing near-complete hot flash elimination within days of their first dose.
- A clinically significant subgroup reports efficacy waning after 3 to 6 months of use, creating a predictable adherence-leak window that threatens long-term retention without proactive patient support.
- Cost and insurance access (especially Medicare exclusion from copay programs) are the top non-clinical reason for discontinuation, with out-of-pocket costs cited as a primary barrier to continued therapy.
- The boxed hepatotoxicity warning is generating real-world anxiety and actual discontinuation events, with at least one patient reporting liver enzymes still abnormal nearly a year after stopping the drug.